ReviewFrontiers in pharmacology2022
Analgesic Alkaloids Derived From Traditional Chinese Medicine in Pain Management.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Curative effect of acupuncture combined with Chinese medicine on cancer pain: Systematic review and meta-analysis.Medicine · 2026Pooled it
- Research hotspots and trends in the application of Chinese herbal medicine for cancer pain management: a bibliometric study.Frontiers in medicine · 2026Pooled it
- Efficacy and safety of TCMs with anti-inflammatory effect in patients with rheumatoid arthritis: A network meta-analysis.Frontiers in immunology · 2023Pooled it
- Topical Traditional Chinese Medicines for Cancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Integrative cancer therapiesPooled it
- Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms.Molecular biology reports · 2026Article
- A drug-drug co-amorphous formulation for enhanced solubility and transdermal absorption of rotundine.International journal of pharmaceutics: X · 2026Article
- Neg-entropy is the true drug target for chronic diseases.Acta pharmaceutica Sinica. B · 2026Review
- Using Integrated Network Pharmacology and Metabolomics to Reveal the Mechanisms of the Combined Intervention of Ligustrazine and Sinomenine in CCI-Induced Neuropathic Pain Rats.International journal of molecular sciences · 2025Article
- Euodiae Fructus: a review of botany, application, processing, phytochemistry, quality control, pharmacology, and toxicology.Frontiers in pharmacology · 2025Review
- Efficacy and Safety of the Bushen Quhan Zhiwang Decoction to Achieve Clinical Deep Remission in Rheumatoid Arthritis: Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.Journal of pain research · 2025Article
- The Utilization of Ultrasound-Guided Regional Nerve Blocks in Anesthetic Management for Fracture Surgery.Journal of pain research · 2025Review
- The Role of Phytochemicals in Managing Neuropathic Pain: How Much Progress Have We Made?Nutrients · 2024Review
- Exploring the safety of lycorine in the central nervous system and its impact on pain-like behaviors in mice.Scientific reports · 2024Article
- Gut-immunity-joint axis: a new therapeutic target for gouty arthritis.Frontiers in pharmacology · 2024Review
- A review on the pharmacology, pharmacokinetics and toxicity of sophocarpine.Frontiers in pharmacology · 2024Review
- Medial septum glutamatergic neurons modulate nociception in chronic neuropathic pain via projections to lateral hypothalamus.Frontiers in pharmacology · 2023Article
- Sinomenine regulates immune cell subsets: Potential neuro-immune intervene for precise treatment of chronic pain.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain is one of the most prevalent health problems. The establishment of chronic pain is complex. Current medication for chronic pain mainly dependent on anticonvulsants, tricyclic antidepressants and opioidergic drugs. However, they have limited therapeutic efficacy, and some even with severe side effects. We turned our interest into alkaloids separated from traditional Chinese medicine (TCM), that usually act on multiple drug targets. In this article, we introduced the best-studied analgesic alkaloids derived from TCM, including tetrahydropalmatine, aloperine, oxysophocarpine, matrine, sinomenine, ligustrazine, evodiamine, brucine, tetrandrine, Stopholidine, and lappaconitine, focusing on their mechanisms and potential clinical applications. To better describe the mechanism of these alkaloids, we adopted the concept of drug-cloud (dCloud) theory. dCloud illustrated the full therapeutic spectrum of multitarget analgesics with two dimensions, which are "direct efficacy", including inhibition of ion channels, activating γ-Aminobutyric Acid/opioid receptors, to suppress pain signal directly; and "background efficacy", including reducing neuronal inflammation/oxidative stress, inhibition of glial cell activation, restoring the balance between excitatory and inhibitory neurotransmission, to cure the root causes of chronic pain. Empirical evidence showed drug combination is beneficial to 30-50% chronic pain patients. To promote the discovery of effective analgesic combinations, we introduced an ancient Chinese therapeutic regimen that combines herbal drugs with "Jun", "Chen", "Zuo", and "Shi" properties. In dCloud, "Jun" drug acts directly on the major symptom of the disease; "Chen" drug generates major background effects; "Zuo" drug has salutary and supportive functions; and "Shi" drug facilitates drug delivery to the targeted tissue. Subsequently, using this concept, we interpreted the therapeutic effect of established analgesic compositions containing TCM derived analgesic alkaloids, which may contribute to the establishment of an alternative drug discovery model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.